AVITA Medical Inc

AVITA Medical, Inc. through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product RECELL system is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company is headquartered in Valencia, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AVITA Medical Inc reports robust Q4 earnings and growth outlook

AVITA Medical's strong financial performance in Q4 2022 and full year 2022, coupled with strategic initiatives and growth projections for 2023, position the company for continued success.
While facing challenges in managing expenses and achieving regulatory approvals, AVITA Medical's focus on innovation, market expansion, and operational efficiency presents opportunities for sustained growth.
Investors should monitor the company's progress in securing PMA approvals, expanding market presence, and optimizing operational costs to capitalize on the projected revenue growth and market opportunities.

AVITA Medical reports robust Q1 earnings, eyes FDA approvals

AVITA Medical Inc. delivered strong financial results in Q1 2023, driven by revenue growth and operational improvements.
The company's strategic priorities for 2023 are on track, with pending FDA applications and new product launches in the pipeline.
While facing challenges in operational transitions and market competition, AVITA Medical remains focused on innovation and growth.

AVITA Medical reports strong Q2 performance with FDA milestones

AVITA Medical had a strong quarter with revenue growth and landmark FDA approvals.
The company faces challenges with increased expenses and supply chain issues.
Opportunities lie in market expansion, new FDA approvals, and international growth strategies.
AVITA Medical aims for realistic growth, focusing on hitting guidance targets to build credibility.

AVITA Medical reports robust revenue growth and strategic international expansion

AVITA Medical Inc's Q3 2023 performance reflects strong revenue growth and strategic initiatives to drive international expansion and profitability by 2025.
The company's focus on core business areas, confidence in growth prospects, and commitment to enhancing patient outcomes position it well for future success.
While facing challenges in pricing strategies and global expansion pace, AVITA Medical is poised to capitalize on opportunities in wound care innovation, regulatory approvals, and international market expansion.

AVITA Medical reports strong earnings, eyes global expansion and profitability

AVITA Medical Inc showcased robust financial performance and strategic advancements in Q4 2023 earnings call.
While facing challenges such as net losses and restructuring, the company is well-positioned for growth.
Opportunities lie in product launches, global expansion, and operational efficiency improvements.
Overall, AVITA Medical's performance and outlook signal a promising trajectory for future success.

AVITA Medical Inc reports Q1 revenue miss, eyes profitability by 2025

AVITA Medical Inc faced challenges in Q1 2024 with revenue falling short of expectations, but the company remains focused on strategic initiatives to drive growth and expand its product portfolio. Despite challenges, AVITA is optimistic about its international expansion efforts and aims to achieve profitability by the third quarter of 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced preliminary unaudited financial highlights for the fourth quarter and full-year 2023, provided financial guidance for the first quarter and full-year 2024, and announced completion of patient enrollment in its post-market study, TONE.

AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update

VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 42nd Annual J.P.

AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the supplement of its RECELL System for full-thickness skin defects. AVITA's expanded FDA label approval has significantly increased its addressable market, with an opportunity in excess of $2.7 billion in the US alone.

AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.

Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance

VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time.

AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference

VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update to its full year 2023 guidance. This update is a result of slower-than-anticipated progression through the customer's Value Analysis Committee (VAC) processes, driven by the expanded label applications of its newest indication, full-thickness skin defects.

AVITA Medical Updates Full Year 2023 Guidance

AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - Cowen Brooks O'Neil - Lake Street Capital Markets John Hester - Bell Potter Ross Osborne - Cantor Fitzgerald Madeline Williams - Wilsons Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Third Quarter 2023 Earnings Call.

AVITA Medical, Inc. (RCEL) Q3 2023 Earnings Call Transcript

VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter September 30, 2023.

AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year

AVITA Medical announced it has entered into a distribution agreement with PolyMedics Innovations, to strategically expand its global presence to Europe.

AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe

VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its third quarter 2023 financial results after the close of the U.S. financial markets on Thursday, November 9, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 10, 2023, at 7:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.

AVITA Medical to Announce Third Quarter 2023 Financial Results

The FDA is asking for more information regarding Avita's Recell Go device. The Recell Go is a more automated version of an already approved product for Avita.

Why Shares of Avita Medical Are Down Monday

VALENCIA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, is pleased to announce that the RECELL® System won Best Product for the second year in a row at the Annual Meeting of the American Association for the Surgery of Trauma (AAST). In its 82nd year, the annual meeting attracts over 700 physicians and scientists focused on the investigation and treatment of various forms of trauma and the application of surgical critical care.

AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time.

AVITA Medical to Present at the Cantor Global Healthcare Conference

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management team will participate in the following upcoming investor conferences:

AVITA Medical to Participate in Upcoming Investor Conferences

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Brooks O'Neil - Lake Street Capital Markets Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Ross Osborne - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. Second Quarter 2023 Earnings Call.

AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript

AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force positioned to capitalize.

AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair

Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?

VALENCIA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced its submission of a premarket approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for RECELL GO™. The supplement follows the original PMA of its RECELL Autologous Cell Harvesting Device and subsequent PMA supplements.

AVITA Medical Submits FDA PMA Supplement for RECELL GO

VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its application for premarket approval (PMA) of its RECELL® System for the treatment of vitiligo.

AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023.

AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer

Avita specializes in devices and therapies to restore skin growth. The FDA's nod means that the company's Recell system can expand beyond applications for burn patients.

Why Shares of Avita Medical Are Soaring Thursday

AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.

AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System

VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the use of its RECELL® System to treat full-thickness skin defects.

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Phillip Dantoin - Piper Sandler Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2023 Earnings Conference Call.

AVITA Medical, Inc. (RCEL) Q1 2023 Earnings Call Transcript

VALENCIA, Calif. and MELBOURNE, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the first quarter March 31, 2023.

News for AVITA Medical Inc Stock (RCEL)